Last updated: July 15, 2026
What is AbbVie v. MSN Pharmaceuticals Inc. case 1:26-cv-00680 about?
The docket number 1:26-cv-00680 identifies a federal patent litigation filed by AbbVie Inc. against MSN Pharmaceuticals Inc.. The action is pursued in the context of FDA small-molecule product entry and generic/biosimilar-type competitive risk, where AbbVie’s claims typically target one or more Orange Book-listed patents tied to an AbbVie reference product.
At present, the specific asserted patents, product, asserted counts (infringement, inducement, willfulness), and requested relief are not provided in the available record for this docket reference alone. Without the docket’s complaint or the asserted-claims list, a complete infringement and validity analysis cannot be constructed to a level suitable for litigation decision-making.
What patents are asserted in AbbVie v. MSN Pharmaceuticals (1:26-cv-00680)?
A litigation-grade patent map requires the complaint’s asserted patent list (publication numbers and claims), plus the FDA application linkage (ANDA/BLA number and Paragraph IV notice contents).
Those elements are not contained in the information provided for 1:26-cv-00680. As a result, there is no basis to enumerate:
- asserted patent numbers and expiration dates,
- claim sets (independent/dependent) at issue,
- whether AbbVie asserts formulation vs. method-of-use vs. manufacturing patents,
- whether MSN is challenging validity under §102/§103/§112 or non-infringement by product/process design changes.
What is the procedural posture of 1:26-cv-00680?
A full procedural posture summary depends on docket events such as:
- date of complaint filing,
- service date,
- defendant answer and affirmative defenses,
- Rule 16 scheduling order,
- claim-construction briefing,
- any stipulated protective order and confidentiality designations,
- motions to dismiss, transfer, severance, summary judgment,
- settlement or consent judgment entries.
Those docket event details are not present in the provided input. No accurate timeline of filing-to-trial track can be produced.
Has MSN Pharmaceuticals filed a Paragraph IV challenge? What does it mean for the case?
For FDA-linked Hatch-Waxman disputes, the core question is whether MSN submitted:
- an ANDA with a Paragraph IV certification,
- a carved-out certification to specific patents,
- or a different legal pathway.
The litigation risk profile depends on whether the notice targets:
- a single dominant formulation patent,
- a method-of-use patent (common for dose-regimen or patient-subset claims),
- or multiple layers of claim families (composition, formulation, and manufacturing process).
The provided record does not include the Paragraph IV notice contents, patent certifications, or ANDA/BLA number, so this analysis cannot be completed.
What motions typically drive AbbVie v. MSN Pharmaceuticals in Hatch-Waxman?
In the absence of docket motion entries, the likely motion set cannot be treated as confirmed. A litigation-accurate analysis must reference actual filings such as:
- motions for judgment on the pleadings,
- motions to dismiss for failure to state a claim or improper venue,
- Daubert motions on expert testimony,
- claim-construction disputes about claim scope and indefiniteness,
- summary judgment on non-infringement and/or lack of enablement.
Because no motion register is included for 1:26-cv-00680, any enumerated “typical motions” would not satisfy a decision-grade litigation summary.
How strong is AbbVie’s patent estate in this specific dispute?
Patent estate strength in a given case is not generic. It is anchored to:
- the asserted claim set breadth,
- prior art mapping and obviousness attack strength,
- prosecution history (estoppel), and
- whether the claims correspond to the product’s actual formulation or use.
Without the asserted patents and claim language for 1:26-cv-00680, there is no basis for a quantified strength assessment (for example, likelihood of surviving invalidity motions or probability of infringement finding).
Does the case include settlement terms or consent judgments?
Settlement and consent judgments are typically reflected by docket entries like:
- stipulation of dismissal,
- settlement agreement redactions,
- “partial dismissal without prejudice,”
- entry of amended schedules,
- or consent injunction terms.
The provided input does not include any settlement-related docket events. A settlement analysis cannot be produced without docket entries.
What generic launch or market timing risks exist from 1:26-cv-00680?
The market timing impact depends on the interplay of:
- the reference product’s exclusivity timeline,
- the asserted patent expiration dates,
- any listed regulatory exclusivities (data exclusivity, 3-year/5-year exclusivity),
- and whether the litigation is likely to reach the 30-month stay end or a faster resolution.
None of the product identity, the Orange Book patent list, or expiration dates are provided for 1:26-cv-00680, so market timing risk cannot be quantified.
What is the FDA Orange Book status for the reference product in this case?
Orange Book status requires:
- product name,
- NDA number,
- and a list of listed patents with their expiration dates and regulatory association.
No NDA/product linkage is included in the provided record, so the Orange Book analysis cannot be stated.
How does AbbVie’s allegations compare with prior AbbVie v. generic disputes?
Comparative analysis requires:
- which AbbVie asset is at issue,
- the claim family type in this case,
- and any previously litigated patents involving similar claim constructions or repeating invalidity arguments.
Without the asserted asset, there is no verified basis for comparison.
What should counsel focus on for infringement and validity in 1:26-cv-00680?
A litigation-focused issue framework must cite:
- specific claim construction disputes,
- specific prior art references pleaded in the defenses,
- and the accused product design elements.
Those are not available from the input, so a claim-level focus plan cannot be produced.
Key Takeaways
- AbbVie Inc. v. MSN Pharmaceuticals Inc. (1:26-cv-00680) is identifiable as a federal patent litigation, but the provided information does not include the asserted patents, accused product, FDA application linkage, or docket events needed for a complete litigation summary.
- A decision-grade analysis covering Paragraph IV scope, patent strength, procedural posture, settlement risk, and launch timing cannot be supported without the complaint and docket filings for this case.
FAQs
- What does the docket number 1:26-cv-00680 indicate about the court and case type?
- How do Paragraph IV certifications drive the schedule and remedies in AbbVie-led Hatch-Waxman suits?
- What documents in a Hatch-Waxman case most directly determine which patents are at issue?
- How do claim constructions typically affect infringement outcomes in formulation versus method-of-use patent cases?
- What docket milestones signal whether a Hatch-Waxman case is heading toward trial versus settlement?
References
- United States District Court docket, AbbVie Inc. v. MSN Pharmaceuticals Inc., No. 1:26-cv-00680 (case identification provided).
